Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab + Relatlimab vs Nivolumab in Resected Stage III-IV Melanoma
2023-507688-20-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Nivolumab + Relatlimab FDC with Nivolumab monotherapy (2 arms). Primary endpoint: Relapse-free survival (RFS). Started Feb 2024; status: completed.
02
Drugs
nivolumabrelatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-507688-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507688-20-00.